ADVFN Logo ADVFN

No pudimos encontrar ningún resultado para:
Asegúrate de que la ortografía sea correcta o intenta ampliar tu búsqueda.

Tendencias Ahora

Listas Principales

Parece que no has iniciado sesión.
Haz clic en el botón de abajo para iniciar sesión y ver tu historial reciente.

Regístrate

¿Ya eres miembro? Iniciar sesión

Los Principales Corredores en Línea

Más Corredores en Línea

Datos
Noticias
Herramientas
Mercados
Descubrir

Hot Features

Follow Feed

Conéctese con traders e inversores en nuestra comunidad Follow Feed.

Flujo de Opciones

Explora datos de opciones completos y utiliza filtros avanzados con Options Flow.

Monitor

Organiza y monitorea tu lista de seguimiento de acciones y activos con Monitor.
Iniciar Sesión Premium IconPremium Help Menu
S&P 500
6,071.17
0.53%
Dow Jones
44,882.13
0.38%
US Dollar vs MXN
20.69805
0.09%
Brent Oil
76.19
0.18%
Bitcoin
104,834.58
0.10%
Pepperstone
Advertisement
Registration Strip Icon for charts Regístrate para obtener gráficos en tiempo real, herramientas de análisis y precios.
Regístrate
  1. Inicio
  2. Invertir
  3. Acciones
  4. Estados Unidos
  5. NASDAQ
  6. Lyra Therapeutics Inc (LYRA)

  7. Lyra Therapeutics Inc (LYRA) Noticias

LYRA

Lyra Therapeutics (LYRA)

Lyra Therapeutics Inc
Fecha:
Ordernar por:
 Showing the most relevant articles for your search:NASDAQ:LYRA
FechaHoraFuenteTítuloSímboloCompañía
10/01/202515:15Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:LYRALyra Therapeutics Inc
10/01/202515:02Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:LYRALyra Therapeutics Inc
14/11/202418:48Edgar (US Regulatory)Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]NASDAQ:LYRALyra Therapeutics Inc
14/11/202415:53Edgar (US Regulatory)Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]NASDAQ:LYRALyra Therapeutics Inc
12/11/202415:24Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:LYRALyra Therapeutics Inc
12/11/202415:01GlobeNewswire Inc.Lyra Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate UpdateNASDAQ:LYRALyra Therapeutics Inc
15/10/202406:00GlobeNewswire Inc.Lyra Therapeutics Fully Enrolls Pivotal Phase 3 ENLIGHTEN 2 Trial of LYR-210 for the Treatment of Chronic RhinosinusitisNASDAQ:LYRALyra Therapeutics Inc
27/09/202406:00GlobeNewswire Inc.Lyra Therapeutics to Present Study Results for LYR-210 and LYR-220 in Two Presentations at the ARS and AAO-HNS Annual MeetingsNASDAQ:LYRALyra Therapeutics Inc
14/08/202415:01GlobeNewswire Inc.Lyra Therapeutics Reports Second Quarter 2024 Financial Results and Provides Corporate UpdateNASDAQ:LYRALyra Therapeutics Inc
07/06/202415:15Edgar (US Regulatory)Form 8-K/A - Current report: [Amend]NASDAQ:LYRALyra Therapeutics Inc
21/05/202408:14GlobeNewswire Inc.Lyra Therapeutics Announces Cost-Cutting Measures to Preserve CapitalNASDAQ:LYRALyra Therapeutics Inc
06/05/202406:59GlobeNewswire Inc.Lyra Therapeutics Reports Topline Results from Phase 3 ENLIGHTEN 1 Trial for LYR-210 in Chronic RhinosinusitisNASDAQ:LYRALyra Therapeutics Inc
30/04/202415:04GlobeNewswire Inc.Lyra Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate UpdateNASDAQ:LYRALyra Therapeutics Inc
26/04/202415:51GlobeNewswire Inc.Lyra Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)NASDAQ:LYRALyra Therapeutics Inc
21/03/202415:01GlobeNewswire Inc.Lyra Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate UpdateNASDAQ:LYRALyra Therapeutics Inc
01/03/202415:01GlobeNewswire Inc.Lyra Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)NASDAQ:LYRALyra Therapeutics Inc
15/02/202408:18Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:LYRALyra Therapeutics Inc
13/02/202415:34Edgar (US Regulatory)Form SC 13G - Statement of acquisition of beneficial ownership by individualsNASDAQ:LYRALyra Therapeutics Inc
07/11/202315:01GlobeNewswire Inc.Lyra Therapeutics Reports Third Quarter 2023 Financial Results and Provides Corporate UpdateNASDAQ:LYRALyra Therapeutics Inc
07/11/202306:00GlobeNewswire Inc.Lyra Therapeutics to Participate in Upcoming Investor ConferencesNASDAQ:LYRALyra Therapeutics Inc
16/10/202306:00GlobeNewswire Inc.Lyra Therapeutics Announces Appointment of Ronan O’Brien as Chief Legal OfficerNASDAQ:LYRALyra Therapeutics Inc
12/09/202306:00GlobeNewswire Inc.Lyra Therapeutics Announces Positive Topline Results from BEACON Phase 2 Study of LYR-220 for the Treatment of Chronic Rhinosinusitis (CRS) in Patients with Prior Ethmoid Sinus SurgeryNASDAQ:LYRALyra Therapeutics Inc
01/09/202315:01Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:LYRALyra Therapeutics Inc
29/08/202306:00GlobeNewswire Inc.Lyra Therapeutics Fully Enrolls Pivotal Phase 3 ENLIGHTEN I Trial of LYR-210 for the Treatment of Chronic RhinosinusitisNASDAQ:LYRALyra Therapeutics Inc
08/08/202315:01GlobeNewswire Inc.Lyra Therapeutics Reports Second Quarter 2023 Financial Results and Provides Corporate UpdateNASDAQ:LYRALyra Therapeutics Inc
13/07/202306:30GlobeNewswire Inc.Lyra Therapeutics to Present at William Blair Virtual Biotechnology ConferenceNASDAQ:LYRALyra Therapeutics Inc
12/07/202317:36Edgar (US Regulatory)Form 4/A - Statement of changes in beneficial ownership of securities: [Amend]NASDAQ:LYRALyra Therapeutics Inc
09/07/202323:15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:LYRALyra Therapeutics Inc
07/07/202315:44Edgar (US Regulatory)Form 424B3 - Prospectus [Rule 424(b)(3)]NASDAQ:LYRALyra Therapeutics Inc
28/06/202315:07Edgar (US Regulatory)Securities Registration Statement (simplified Form) (s-3)NASDAQ:LYRALyra Therapeutics Inc
 Showing the most relevant articles for your search:NASDAQ:LYRA

Su Consulta Reciente

FX
EURUSD
Euro vs US Dollar
SPI
SP500
S&P 500
USI
USTECH100
US Tech 100
COIN
AVAXUSD
Avalanche
NYSE
XOM
Exxon Mobil
NASDAQ
AAPL
Apple
USOTC
ADDYY
Adidas (QX)
NYSE
DIS
Walt Disney
COIN
BTCUSD
Bitcoin
NASDAQ
NVDA
NVIDIA
CCOM
US500
US 500
FX
USDMXN
US Dollar vs MXN
COIN
DOGEUSD
Dogecoin
USOTC
BASFY
BASF (QX)
NYSE
CVX
Chevron
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

México
Empresa
Negocios
Popular
Obtener la aplicación
App Store
Google Play

Soporte: (55) 4170 8128 | soporte@advfn.mx

Al acceder a los servicios disponibles de ADVFN usted acepta quedar sujerto a los Términos y Condiciones

© 2025 ADVFN PLC - Todos los derechos reservados

Quitar anuncios

Suscríbete a una experiencia sin publicidad

Sin anuncios

Pruébalo ahora

Mantenga los anuncios